Lee Kevin 4
4 · BICYCLE THERAPEUTICS PLC · Filed Jul 7, 2026
Research Summary
AI-generated summary of this filing
Bicycle Therapeutics (BCYC) CEO Kevin Lee Sells Shares
What Happened
Kevin Lee, CEO of Bicycle Therapeutics plc (BCYC), reported two open‑market sales totaling 7,642 shares for approximately $32,700. On 2026-07-02 he sold 5,905 shares at a weighted average price of $4.27 for $25,214; on 2026-07-06 he sold 1,737 shares at a weighted average price of $4.31 for $7,486. These were sales, not purchases; the larger 7/2 sale was a mandatory "sell‑to‑cover" to satisfy tax withholding on vested RSUs rather than a discretionary sale.
Key Details
- Transaction dates and prices:
- 2026-07-02: 5,905 shares sold at $4.27 (weighted average; individual prices ranged $4.26–$4.29). (Footnotes F1, F2)
- 2026-07-06: 1,737 shares sold at $4.31 (weighted average; individual prices ranged $4.30–$4.31). (Footnote F3)
- Total sold: 7,642 shares for ~$32,700.
- Shares owned after transaction: not disclosed in the provided filing extract.
- Footnotes:
- F1: 7/2 sale was mandatory "sell‑to‑cover" to satisfy statutory tax withholding on RSU vesting — not a discretionary sale.
- F2/F3: reported prices are weighted averages; the filer can provide a breakdown of shares sold at each price within the stated ranges upon request.
- Filing date: 2026-07-07. Form 4s are generally due within two business days of a transaction — the 7/6 sale was reported promptly, while the 7/2 sale was reported five days later.
Context
A sell‑to‑cover tied to RSU vesting is routine and reflects tax obligations, not necessarily the CEO's view on the company. In general, purchases by insiders often carry more signal than routine or mandated sales; these transactions should be viewed as administrative unless additional information indicates otherwise.
Insider Transaction Report
- Sale
Ordinary Shares
[F1][F2]2026-07-02$4.27/sh−5,905$25,214→ 605,408 total - Sale
Ordinary Shares
[F1][F3]2026-07-06$4.31/sh−1,737$7,486→ 603,671 total
Footnotes (3)
- [F1]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.31 inclusive.